Results 121 to 130 of about 5,666,574 (155)
Some of the next articles are maybe not open access.
2020
Thyroid eye disease is an autoimmune condition with an active and inactive phase resulting in proptosis, eyelid retraction, and periorbital edema of varying severity. Symptoms range from mild eye irritation to vision loss from compressive optic neuropathy requiring medical and possibly acute surgical intervention.
Jeffrey Nerad, Trevor Smith
openaire +1 more source
Thyroid eye disease is an autoimmune condition with an active and inactive phase resulting in proptosis, eyelid retraction, and periorbital edema of varying severity. Symptoms range from mild eye irritation to vision loss from compressive optic neuropathy requiring medical and possibly acute surgical intervention.
Jeffrey Nerad, Trevor Smith
openaire +1 more source
Non-surgical treatment for eyelid retraction in thyroid eye disease (TED)
British Journal of Ophthalmology, 2017Thyroid eye disease (TED) is an autoimmune condition with an unpredictable course that may lead to permanent facial disfigurement. Eyelid retraction is one of the most common findings, and frequently demands attention due to ocular exposure and impaired cosmesis.
Ana Beatriz Diniz, Grisolia +4 more
openaire +2 more sources
Eye, 2020
Teprotumumab, a blocking antibody to the insulin like growth factor 1 receptor (IGF-1R) has been shown to significantly reduce proptosis in recent phase 2 and 3 trials in patients with inflammatory thyroid eye disease (TED). Herein, we investigate the impact of teprotumumab on patients with non-inflammatory TED.
Shoaib Ugradar +5 more
openaire +2 more sources
Teprotumumab, a blocking antibody to the insulin like growth factor 1 receptor (IGF-1R) has been shown to significantly reduce proptosis in recent phase 2 and 3 trials in patients with inflammatory thyroid eye disease (TED). Herein, we investigate the impact of teprotumumab on patients with non-inflammatory TED.
Shoaib Ugradar +5 more
openaire +2 more sources
International Ophthalmology, 2021
Teprotumumab (TPT) is a type I insulin-like growth factor receptor inhibitor, marketed as Tepezza; recently USFDA approved it for the treatment of thyroid eye disease (thyroid-associated ophthalmopathy (TAO), Graves ophthalmopathy/orbitopathy) in the USA.
Faraat Ali +3 more
openaire +2 more sources
Teprotumumab (TPT) is a type I insulin-like growth factor receptor inhibitor, marketed as Tepezza; recently USFDA approved it for the treatment of thyroid eye disease (thyroid-associated ophthalmopathy (TAO), Graves ophthalmopathy/orbitopathy) in the USA.
Faraat Ali +3 more
openaire +2 more sources
British Journal of Ophthalmology, 2011
To develop and test a user-friendly questionnaire for rapidly assessing quality of life (QOL) in thyroid eye disease (TED).A three-item questionnaire, the TED-QOL, was designed and compared to the 16-item Graves Ophthalmopathy (GO)-QOL and the nine-item GO-Quality of Life Scale (QLS).
Tessa, Fayers, Peter J, Dolman
openaire +2 more sources
To develop and test a user-friendly questionnaire for rapidly assessing quality of life (QOL) in thyroid eye disease (TED).A three-item questionnaire, the TED-QOL, was designed and compared to the 16-item Graves Ophthalmopathy (GO)-QOL and the nine-item GO-Quality of Life Scale (QLS).
Tessa, Fayers, Peter J, Dolman
openaire +2 more sources
Late relapse of thyroid eye disease (TED)
Endocrine Abstracts, 2022Noel Murphy +4 more
openaire +1 more source
Reconsidering the role of thyroidectomy in thyroid eye disease (TED) patients
Endocrine Abstracts, 2022Zuzana Sipkova +5 more
openaire +1 more source
Diagnosing and treating Compressive-Optic-Neuropathy in Thyroid Eye Disease (TED-CON)
This cumulative postdoctoral thesis focuses on the topic of diagnosing optic nerve compression - a severe complication of Thyroid Eye Disease (TED). Beyond the analysis of the diagnostic methods, the publications included in thesis help us to detect subclinical cases and understand the treatment methods to preserve the vision in such patients. Althoughopenaire +1 more source
A link between thyroid eye disease (TED) and diabetes?
Endocrine Abstracts, 2019Soma Farag +9 more
openaire +1 more source
Ophthalmic Plastic & Reconstructive Surgery
Purpose: Monocytes are involved in autoimmune diseases, including Graves disease and thyroid eye disease (TED). The authors studied the expression and function of the thyrotropin receptor (TSHR) in all subsets (classical: CD14 ++ , CD16
Raymond S, Douglas +4 more
openaire +2 more sources
Purpose: Monocytes are involved in autoimmune diseases, including Graves disease and thyroid eye disease (TED). The authors studied the expression and function of the thyrotropin receptor (TSHR) in all subsets (classical: CD14 ++ , CD16
Raymond S, Douglas +4 more
openaire +2 more sources